These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 15769642)

  • 1. Insulin resistance in NASH.
    Choudhury J; Sanyal AJ
    Front Biosci; 2005 May; 10():1520-33. PubMed ID: 15769642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The metabolic abnormalities associated with non-alcoholic fatty liver disease.
    Haque M; Sanyal AJ
    Best Pract Res Clin Gastroenterol; 2002 Oct; 16(5):709-31. PubMed ID: 12406441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-Alcoholic Fatty Liver Disease.
    Engin A
    Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease.
    Choudhury J; Sanyal AJ
    Clin Liver Dis; 2004 Aug; 8(3):575-94, ix. PubMed ID: 15331065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A fresh look at NASH pathogenesis. Part 1: the metabolic movers.
    Larter CZ; Chitturi S; Heydet D; Farrell GC
    J Gastroenterol Hepatol; 2010 Apr; 25(4):672-90. PubMed ID: 20492324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From the metabolic syndrome to NAFLD or vice versa?
    Vanni E; Bugianesi E; Kotronen A; De Minicis S; Yki-Järvinen H; Svegliati-Baroni G
    Dig Liver Dis; 2010 May; 42(5):320-30. PubMed ID: 20207596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease.
    Parekh S; Anania FA
    Gastroenterology; 2007 May; 132(6):2191-207. PubMed ID: 17498512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pathophysiology of non-alcoholic steatohepatitis. An insulin resistance overview].
    Macías-Rodríguez RU; Torre A
    Rev Invest Clin; 2009; 61(2):161-72. PubMed ID: 19637730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of microsomal triglyceride transfer protein in nonalcoholic steatohepatitis in novel spontaneous mouse model.
    Shindo N; Fujisawa T; Sugimoto K; Nojima K; Oze-Fukai A; Yoshikawa Y; Wang X; Yasuda O; Ikegami H; Rakugi H
    J Hepatol; 2010 Jun; 52(6):903-12. PubMed ID: 20392512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic insulin resistance is associated with increased apoptosis and fibrogenesis in nonalcoholic steatohepatitis and chronic hepatitis C.
    García-Monzón C; Lo Iacono O; Mayoral R; González-Rodríguez A; Miquilena-Colina ME; Lozano-Rodríguez T; García-Pozo L; Vargas-Castrillón J; Casado M; Boscá L; Valverde AM; Martín-Sanz P
    J Hepatol; 2011 Jan; 54(1):142-52. PubMed ID: 20888662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines.
    Polyzos SA; Kountouras J; Zavos C
    Curr Mol Med; 2009 Apr; 9(3):299-314. PubMed ID: 19355912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin resistance in nonalcoholic fatty liver disease.
    Bugianesi E; Moscatiello S; Ciaravella MF; Marchesini G
    Curr Pharm Des; 2010 Jun; 16(17):1941-51. PubMed ID: 20370677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin resistance, inflammation, and non-alcoholic fatty liver disease.
    Tilg H; Moschen AR
    Trends Endocrinol Metab; 2008 Dec; 19(10):371-9. PubMed ID: 18929493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-alcoholic fatty liver disease and insulin resistance.
    Machado M; Cortez-Pinto H
    Eur J Gastroenterol Hepatol; 2005 Aug; 17(8):823-6. PubMed ID: 16003131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome.
    Marchesini G; Brizi M; Bianchi G; Tomassetti S; Bugianesi E; Lenzi M; McCullough AJ; Natale S; Forlani G; Melchionda N
    Diabetes; 2001 Aug; 50(8):1844-50. PubMed ID: 11473047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonalcoholic steatohepatitis versus steatosis: adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism.
    Musso G; Cassader M; De Michieli F; Rosina F; Orlandi F; Gambino R
    Hepatology; 2012 Sep; 56(3):933-42. PubMed ID: 22684858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanisms of steatosis in nonalcoholic fatty liver disease.
    Pettinelli P; Obregón AM; Videla LA
    Nutr Hosp; 2011; 26(3):441-50. PubMed ID: 21892559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Fatty liver and global cardiometabolic risk].
    Szollár L
    Orv Hetil; 2010 Nov; 151(47):1946-50. PubMed ID: 21071306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of hepassocin in the development of non-alcoholic fatty liver disease.
    Wu HT; Lu FH; Ou HY; Su YC; Hung HC; Wu JS; Yang YC; Wu CL; Chang CJ
    J Hepatol; 2013 Nov; 59(5):1065-72. PubMed ID: 23792031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis.
    Svegliati-Baroni G; Saccomanno S; Rychlicki C; Agostinelli L; De Minicis S; Candelaresi C; Faraci G; Pacetti D; Vivarelli M; Nicolini D; Garelli P; Casini A; Manco M; Mingrone G; Risaliti A; Frega GN; Benedetti A; Gastaldelli A
    Liver Int; 2011 Oct; 31(9):1285-97. PubMed ID: 21745271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.